Hypothesis: Bariatric surgery offers better glycemic control for patients with Type 2 Diabetes Mellitus in comparison to standard therapies of diet, exercise, and pharmaceuticals.
Methods: A retrospective literature research was conducted using several scholarly databases to collect and review information relevant to the hypothesis. The search engines included but were not limited to Google Scholar, PubMed, MedlinePlus, and ClinicalTrials.gov. The research was not limited by country of origin but was restricted to publications in English. Articles that did not meet the inclusion criteria were rejected and studies that met the exclusion criteria were eliminated from the data pool.
Results: Patients who received Bariatric procedures (i.e. Roux-En-Y Gastric Bypass and Sleeve Gastrectomy) consistently had a greater decrease in glycosylated hemoglobin values compared to patients who received standard anti-diabetic therapy. The results from the data were synthesized into an Evidence Table (Appendix-Table 3).
Conclusion: The evidence suggests that Bariatric surgery is a more effective therapy for patients with Type 2 Diabetes Mellitus compared to conventional treatment. Most studies in this review focused on moderate to morbidly obese patients who suffer from diabetes. More research is required to elucidate which subset of patients with Type 2 Diabetes Mellitus would benefit from metabolic surgery. Future research should examine the benefits and risks of the application